US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
US6057287A
(en)
|
1994-01-11 |
2000-05-02 |
Dyax Corp. |
Kallikrein-binding "Kunitz domain" proteins and analogues thereof
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
EP1012184B1
(en)
*
|
1997-07-14 |
2007-10-10 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US7270809B2
(en)
*
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
BR9915548A
(pt)
|
1998-10-16 |
2001-08-14 |
Biogen Inc |
Proteìnas de fusão de interferon-beta e usos
|
DE69930015T2
(de)
|
1998-10-16 |
2006-10-12 |
Biogen Idec Ma Inc., Cambridge |
Polymerkonjugate von interferon-beta-1a und deren verwendungen
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
AR029337A1
(es)
*
|
1999-03-02 |
2003-06-25 |
Schering Corp |
Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
US6849254B1
(en)
|
1999-04-19 |
2005-02-01 |
Schering Corporation |
HCV combination therapy
|
WO2001026677A1
(fr)
*
|
1999-10-12 |
2001-04-19 |
Santen Pharmaceutical Co., Ltd. |
Complexe a base d'interferon et son utilisation en medecine
|
SK8292002A3
(en)
*
|
1999-11-12 |
2002-12-03 |
Maxygen Holdings Ltd |
A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
|
CN1309423C
(zh)
|
1999-11-12 |
2007-04-11 |
马克西根控股公司 |
干扰素γ偶联物
|
ES2327606T3
(es)
|
2000-01-10 |
2009-11-02 |
Maxygen Holdings Ltd |
Conjugados de g-csf.
|
DE60138364D1
(de)
|
2000-02-11 |
2009-05-28 |
Bayer Healthcare Llc |
Gerinnungsfaktor vii oder viia konjugate
|
AU2001249120A1
(en)
*
|
2000-03-09 |
2001-09-17 |
Schering Corporation |
Hiv immune adjuvant therapy
|
KR100353392B1
(ko)
*
|
2000-03-13 |
2002-09-18 |
선바이오(주) |
높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법
|
US6476062B2
(en)
|
2000-03-30 |
2002-11-05 |
Schering Corporation |
Chemokine receptor antagonists
|
ES2256234T3
(es)
*
|
2000-05-16 |
2006-07-16 |
Lipoxen Technologies Limited |
Derivatizacion de proteinas en solucion acuosa.
|
AU2001280035A1
(en)
*
|
2000-07-26 |
2002-02-05 |
Ramot University Authority For Applied Research And Industrial Development Ltd. |
Intracellular delivery system for protein phosphatases and other polypeptides
|
US7208167B2
(en)
*
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
CN1454097A
(zh)
*
|
2000-09-08 |
2003-11-05 |
格莱风治疗公司 |
聚合物修饰的合成的蛋白质类
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
ES2367891T3
(es)
|
2000-09-29 |
2011-11-10 |
Schering Corporation |
Interleucina-10 pegilada.
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
ATE432288T1
(de)
|
2001-02-27 |
2009-06-15 |
Maxygen Aps |
Neue interferon-beta-ähnliche moleküle
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
US7038015B2
(en)
*
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
US6835802B2
(en)
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
*
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7049285B2
(en)
*
|
2001-10-31 |
2006-05-23 |
Myung-Ok Park |
Biocompatible polymers including peptide spacer
|
KR100480430B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-베타와 폴리에틸렌글리콜 유도체의 배합체
|
KR100480429B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
|
EP1461067A1
(en)
*
|
2001-12-07 |
2004-09-29 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
WO2003061577A2
(en)
|
2002-01-18 |
2003-07-31 |
Biogen Idec Ma Inc. |
Polyalkylene glycol with moiety for conjugating biologically active compound
|
WO2003078461A1
(en)
*
|
2002-03-20 |
2003-09-25 |
Biopolymed Inc. |
Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
|
EP2298278B1
(en)
|
2002-06-07 |
2015-11-11 |
Dyax Corp. |
Prevention and reduction of blood loss and inflammatory response
|
US7153829B2
(en)
|
2002-06-07 |
2006-12-26 |
Dyax Corp. |
Kallikrein-inhibitor therapies
|
CN1671420A
(zh)
|
2002-06-21 |
2005-09-21 |
诺和诺德医疗保健公司 |
Peg化因子ⅶ糖型
|
WO2004002999A2
(en)
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
|
CA2491178A1
(en)
*
|
2002-07-03 |
2004-01-15 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
SI2386310T1
(sl)
*
|
2002-08-28 |
2019-03-29 |
Dyax Corp. |
Metode za ohranjanje organov in tkiv
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
CA2503594C
(en)
*
|
2002-11-15 |
2011-05-10 |
Doris Brugger |
Positional isomers of peg ifn alpha 2a
|
RS20050502A
(en)
|
2002-12-26 |
2007-08-03 |
Mountain View Pharmaceuticals Inc., |
Polymer conjugates of interferon- beta with enhanced biological potency
|
RS20050501A
(en)
*
|
2002-12-26 |
2007-08-03 |
Mountain View Pharmaceuticals Inc., |
Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
US20050079155A1
(en)
*
|
2003-03-20 |
2005-04-14 |
Xencor, Inc. |
Generating protein pro-drugs using reversible PPG linkages
|
US20050281778A1
(en)
*
|
2003-03-28 |
2005-12-22 |
Myung-Ok Park |
Human growth hormone conjugated with biocompatible polymer
|
JP2006521372A
(ja)
*
|
2003-03-28 |
2006-09-21 |
バイオポリメド インコーポレーテッド |
生物学的活性物質と生体適合性高分子の1:1接合体、この製造方法とこれを含む薬学組成物
|
US20060134736A1
(en)
*
|
2003-03-28 |
2006-06-22 |
Jacobs John W |
Human growth hormone conjugated with biocompatible polymer
|
DE602004025799D1
(de)
|
2003-04-15 |
2010-04-15 |
Glaxosmithkline Llc |
Humane il-18 substitutionsmutanten und deren konjugate
|
EP2390262A1
(en)
|
2003-05-16 |
2011-11-30 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
CA2734052A1
(en)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
AU2004288128A1
(en)
*
|
2003-07-31 |
2005-05-19 |
Anticancer, Inc. |
The use of PLP with PEG-rMETase in vivo for enhanced efficacy
|
EP2263684A1
(en)
|
2003-10-10 |
2010-12-22 |
Novo Nordisk A/S |
IL-21 derivatives
|
EP2407470A3
(en)
|
2003-10-14 |
2015-06-10 |
F. Hoffmann-La Roche Ltd. |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
|
EP2633866A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
WO2005042563A2
(en)
*
|
2003-10-22 |
2005-05-12 |
Akzo Nobel N.V. |
Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration
|
US7407973B2
(en)
*
|
2003-10-24 |
2008-08-05 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
US20070258946A1
(en)
*
|
2003-12-23 |
2007-11-08 |
Blatt Lawrence M |
Combination Therapy for Treating Hepatitis C Virus Infection
|
CA2553528C
(en)
*
|
2004-01-21 |
2012-12-04 |
Nektar Therapeutics Al, Corporation |
Method of preparing propionic acid-terminated polymers
|
AU2005319099B2
(en)
|
2004-02-02 |
2010-09-16 |
Ambrx, Inc. |
Modified human growth hormone
|
GB2429207A
(en)
|
2004-02-02 |
2007-02-21 |
Ambrx Inc |
Modified human interferon polypeptides and their uses
|
WO2005084303A2
(en)
*
|
2004-03-01 |
2005-09-15 |
Enzon Pharmaceuticals, Inc. |
Interferon-beta polymer conjugates
|
KR20120134158A
(ko)
*
|
2004-03-17 |
2012-12-11 |
안티캔서, 인코포레이티드 |
폴리에틸렌 글리콜(peg) 단백질 결합을 증가시키기 위한 방법
|
EP1586334A1
(en)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugates with peg
|
WO2005123113A2
(en)
*
|
2004-06-14 |
2005-12-29 |
Intermune, Inc. |
Interferon compositions and methods of use thereof
|
US20050281872A1
(en)
*
|
2004-06-16 |
2005-12-22 |
Peter Summerville |
Enhanced compliance antiviral medicaments and methods of manufacture and use
|
KR101699142B1
(ko)
|
2004-06-18 |
2017-01-23 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
CN101027318B
(zh)
|
2004-07-19 |
2016-05-25 |
比奥孔有限公司 |
胰岛素-低聚物共轭物,制剂及其用途
|
JP2008515774A
(ja)
|
2004-08-03 |
2008-05-15 |
ダイアックス コーポレイション |
hK1結合タンパク質
|
DE602005022895D1
(de)
|
2004-08-12 |
2010-09-23 |
Schering Corp |
Stabile pegylierte interferon-formulierung
|
RU2433124C2
(ru)
|
2004-09-14 |
2011-11-10 |
Фармассет, Инк. |
Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
|
US7235530B2
(en)
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
US8080391B2
(en)
|
2004-12-22 |
2011-12-20 |
Ambrx, Inc. |
Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
|
EP1836298B1
(en)
|
2004-12-22 |
2012-01-18 |
Ambrx, Inc. |
COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
US7365127B2
(en)
*
|
2005-02-04 |
2008-04-29 |
Enzon Pharmaceuticals, Inc. |
Process for the preparation of polymer conjugates
|
WO2006105511A1
(en)
|
2005-03-31 |
2006-10-05 |
The General Hospital Corporation |
Monitoring and modulating hgf/hgfr activity
|
ATE529442T1
(de)
|
2005-06-03 |
2011-11-15 |
Ambrx Inc |
Verbesserte humane interferon-moleküle und ihre verwendungen
|
ES2553160T3
(es)
|
2005-06-17 |
2015-12-04 |
Novo Nordisk Health Care Ag |
Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
|
JP2009503111A
(ja)
*
|
2005-08-04 |
2009-01-29 |
ネクター セラピューティックス エイエル,コーポレイション |
G−csf部分および重合体の複合体
|
PT2407486T
(pt)
|
2005-08-19 |
2018-02-21 |
Univ Pennsylvania |
Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
|
PT2339014E
(pt)
|
2005-11-16 |
2015-10-13 |
Ambrx Inc |
Métodos e composições compreendendo aminoácidos não-naturais
|
CU23556A1
(es)
*
|
2005-11-30 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
|
AU2007205545B9
(en)
|
2006-01-12 |
2012-10-18 |
Hokusan Co. Ltd. |
Oral composition containing interferon-alpha
|
ITMI20060612A1
(it)
*
|
2006-03-30 |
2007-09-30 |
Keryos Spa |
New activaded poly-ethylene glycols-and related polymers and their applications
|
WO2007126950A1
(en)
*
|
2006-03-31 |
2007-11-08 |
Schering Corporation |
Parenteral low dose type 1 interferons for bladder cancer
|
JP5313129B2
(ja)
|
2006-05-02 |
2013-10-09 |
アロザイン, インコーポレイテッド |
非天然アミノ酸置換ポリペプチド
|
US20080096819A1
(en)
*
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
EP2029738A2
(en)
|
2006-05-24 |
2009-03-04 |
Novo Nordisk Health Care AG |
Factor ix analogues having prolonged in vivo half life
|
US20070282170A1
(en)
*
|
2006-05-30 |
2007-12-06 |
Sundaram Ravikumar |
Rake Retractor and Needle Assembly for Minimally Invasive Surgical Applications
|
US8008948B2
(en)
*
|
2006-07-06 |
2011-08-30 |
Denso Corporation |
Peak voltage detector circuit and binarizing circuit including the same circuit
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
JP2010510171A
(ja)
*
|
2006-08-21 |
2010-04-02 |
ユナイテッド セラピューティクス コーポレーション |
ウイルス感染症の治療のための併用療法
|
DK2615108T3
(en)
|
2006-09-08 |
2017-01-30 |
Ambrx Inc |
Modified human plasma polypeptide or fc scaffolds and their applications
|
WO2008030614A2
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Suppressor trna transcription in vertebrate cells
|
ATE487497T1
(de)
*
|
2006-09-29 |
2010-11-15 |
Canji Inc |
Verfahren und zusammensetzungen für gentherapie
|
US8679472B1
(en)
|
2006-10-05 |
2014-03-25 |
Merck, Sharp & Dohme Corp. |
Crystal of human interferon alpha 2B in complex with zinc
|
KR101079993B1
(ko)
*
|
2006-11-17 |
2011-11-04 |
동아제약주식회사 |
폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
|
BRPI0717674A2
(pt)
*
|
2006-11-24 |
2014-04-08 |
Cadila Healthcare Ltd |
' formulação compreendendo conjugados de peg-interferon alfa, processo de liofilização da formulação e formulação liofilizada '
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
KR20140012199A
(ko)
|
2007-03-30 |
2014-01-29 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
CN103965347B
(zh)
|
2007-05-02 |
2017-07-18 |
Ambrx公司 |
经修饰干扰素β多肽和其用途
|
CN101361968B
(zh)
|
2007-08-06 |
2011-08-03 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗脂肪肝中的应用
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
CA2707840A1
(en)
*
|
2007-08-20 |
2009-02-26 |
Allozyne, Inc. |
Amino acid substituted molecules
|
US8597634B2
(en)
*
|
2007-09-04 |
2013-12-03 |
Biosteed Gene Expression Tech. Co., Ltd. |
Interferon alpha-2a modified by polyethylene glycol and methods of preparation thereof
|
PT2186830E
(pt)
*
|
2007-09-04 |
2012-06-20 |
Biosteed Gene Expression Tech Co Ltd |
Interferão alfa 2b modificado com polietilenoglicol e método de preparação e aplicações do mesmo
|
WO2009050738A2
(en)
*
|
2007-10-16 |
2009-04-23 |
Biocon Limited |
An orally administerable solid pharmaceutical composition and a process thereof
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
AU2008326324B9
(en)
|
2007-11-20 |
2012-11-15 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
EP3103880A1
(en)
|
2008-02-08 |
2016-12-14 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
WO2010005807A2
(en)
|
2008-07-08 |
2010-01-14 |
Board Of Regents, The University Of Texas System |
Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
|
UA118536C2
(uk)
|
2008-07-23 |
2019-02-11 |
Амбркс, Інк. |
Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
|
TWI421093B
(zh)
*
|
2008-07-31 |
2014-01-01 |
Pharmaessentia Corp |
胜肽-聚合物綴合物
|
EP2344201A1
(en)
*
|
2008-09-17 |
2011-07-20 |
Nektar Therapeutics |
Oligomer-protease inhibitor conjugates
|
EP3216800A1
(en)
|
2008-09-26 |
2017-09-13 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
MX348657B
(es)
|
2008-09-26 |
2017-06-21 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
EP3025727A1
(en)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Methods of treating liver disease
|
EP3348281B1
(en)
|
2008-12-17 |
2023-07-05 |
Merck Sharp & Dohme Corp. |
Mono- and di-peg il-10 production; and uses
|
EA201100851A1
(ru)
|
2008-12-23 |
2012-04-30 |
Фармассет, Инк. |
Аналоги нуклеозидов
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
NZ593648A
(en)
|
2008-12-23 |
2013-09-27 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
CN102448458B
(zh)
|
2009-03-18 |
2015-07-22 |
小利兰·斯坦福大学理事会 |
治疗黄病毒科病毒感染的方法和组合物
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
NZ600363A
(en)
|
2009-12-21 |
2014-07-25 |
Ambrx Inc |
Modified porcine somatotropin polypeptides and their uses
|
CN102753573A
(zh)
|
2009-12-21 |
2012-10-24 |
Ambrx公司 |
经过修饰的牛促生长素多肽和其用途
|
LT2521568T
(lt)
|
2010-01-06 |
2018-12-10 |
Dyax Corp. |
Plazmos kalikreiną surišantys baltymai
|
WO2011107591A1
(en)
|
2010-03-05 |
2011-09-09 |
Rigshospitalet |
Chimeric inhibitor molecules of complement activation
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
EP2569331A1
(en)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptide inhibitors of vla4
|
RU2447083C1
(ru)
*
|
2010-07-20 |
2012-04-10 |
Закрытое Акционерное Общество "Биокад" |
НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
BR112013003522B1
(pt)
|
2010-08-17 |
2021-05-25 |
Ambrx, Inc. |
polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
|
CN102380091A
(zh)
|
2010-08-31 |
2012-03-21 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗病毒性肝炎中的应用
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
AR084044A1
(es)
|
2010-11-30 |
2013-04-17 |
Pharmasset Inc |
Compuestos 2’-espiro-nucleosidos
|
BR112013017080A8
(pt)
|
2011-01-06 |
2023-05-09 |
Dyax Corp |
Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
BR112014000055A2
(pt)
|
2011-07-01 |
2017-06-13 |
Bayer Ip Gmbh |
polipeptídeos de fusão de relaxina e usos dos mesmos
|
WO2013011113A1
(en)
|
2011-07-20 |
2013-01-24 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for determining treatment response in patients infected with hcv genotype 4
|
WO2013024156A2
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
|
WO2013024158A1
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
SG11201402899TA
(en)
|
2011-12-06 |
2014-07-30 |
Univ Leland Stanford Junior |
Methods and compositions for treating viral diseases
|
WO2013174988A1
(en)
|
2012-05-24 |
2013-11-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
|
EP3505534A1
(en)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
|
SA113340642B1
(ar)
|
2012-06-15 |
2015-09-15 |
فايزر إنك |
أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
WO2014033266A1
(en)
|
2012-08-31 |
2014-03-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
|
BR112015004022B1
(pt)
|
2012-08-31 |
2023-04-25 |
Sutro Biopharma, Inc |
Aminoácidos modificados compreendendo um grupo azido
|
EA021610B1
(ru)
*
|
2013-03-28 |
2015-07-30 |
Илья Александрович МАРКОВ |
Жидкое противовирусное лекарственное средство
|
EA021643B1
(ru)
*
|
2013-03-28 |
2015-07-30 |
Илья Александрович МАРКОВ |
Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
|
EA023360B1
(ru)
*
|
2013-03-28 |
2016-05-31 |
Илья Александрович МАРКОВ |
Линейный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
|
JP2016519108A
(ja)
|
2013-04-18 |
2016-06-30 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
インターロイキン−10を疾病及び疾患の治療に用いる方法
|
WO2014204816A2
(en)
|
2013-06-17 |
2014-12-24 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
ES2792503T3
(es)
|
2013-08-27 |
2020-11-11 |
Gilead Pharmasset Llc |
Formulación combinada de dos compuestos antivirales
|
US10010588B2
(en)
|
2013-08-30 |
2018-07-03 |
Armo Biosciences, Inc. |
Methods of using pegylated interleukin-10 for treating hyperlipidemia
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
KR20160079114A
(ko)
|
2013-11-11 |
2016-07-05 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
|
US10428158B2
(en)
|
2014-03-27 |
2019-10-01 |
Dyax Corp. |
Compositions and methods for treatment of diabetic macular edema
|
US11311519B2
(en)
|
2014-05-01 |
2022-04-26 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
US10076512B2
(en)
|
2014-05-01 |
2018-09-18 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
DK3137078T3
(da)
|
2014-05-01 |
2019-06-11 |
Eiger Biopharmaceuticals Inc |
Behandling af hepatitis delta-virusinfektion
|
RU2554761C1
(ru)
*
|
2014-05-13 |
2015-06-27 |
Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" |
Противоэнтеровирусное и иммуностимулирующее средство
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
KR101736870B1
(ko)
*
|
2014-08-20 |
2017-05-18 |
한국코러스 주식회사 |
인터페론 접합체를 포함하는 복합체 및 이의 제조방법
|
JP2017536098A
(ja)
|
2014-10-14 |
2017-12-07 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
インターロイキン−15組成物及びその使用
|
WO2016064817A1
(en)
|
2014-10-22 |
2016-04-28 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
KR20240024362A
(ko)
|
2014-10-24 |
2024-02-23 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 fgf-21 폴리펩티드 및 그의 용도
|
EA037151B1
(ru)
|
2014-11-06 |
2021-02-11 |
Фармаэссентия Корпорейшн |
Способ лечения с использованием пегилированного интерферона
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
KR102514971B1
(ko)
|
2015-04-21 |
2023-03-27 |
아이거 바이오파마슈티컬스 인코포레이티드 |
로나파르닙 및 리토나버를 포함하는 약제 조성물
|
AU2016268403A1
(en)
|
2015-05-28 |
2017-12-07 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
JP7053453B2
(ja)
|
2015-08-25 |
2022-04-12 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を治療するためのインターロイキン10の使用方法
|
JP7187315B2
(ja)
|
2015-11-04 |
2022-12-12 |
アイガー・バイオファーマシューティカルズ・インコーポレイテッド |
デルタ型肝炎ウイルス感染の処置
|
BR112018011622A2
(pt)
|
2015-12-11 |
2018-11-27 |
Dyax Corp |
método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
|
WO2017181143A1
(en)
|
2016-04-15 |
2017-10-19 |
Generon (Shanghai) Corporation, Ltd. |
Use of il-22 in treating necrotizing enterocolitis
|
CN106539557A
(zh)
*
|
2016-10-08 |
2017-03-29 |
西安交通大学 |
一种基于恒速静脉输入的药代动力学参数的测定方法
|
KR102459469B1
(ko)
|
2016-11-14 |
2022-10-26 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
US20190374611A1
(en)
|
2017-01-18 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
|
CN110637027A
(zh)
|
2017-02-08 |
2019-12-31 |
百时美施贵宝公司 |
包含药代动力学增强子的修饰的松弛素多肽及其用途
|
WO2019020593A1
(en)
|
2017-07-25 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
|
RU2678332C1
(ru)
|
2017-09-08 |
2019-01-28 |
Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") |
Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
|
US20220056093A1
(en)
|
2018-09-11 |
2022-02-24 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
EP3867265A1
(en)
|
2018-10-19 |
2021-08-25 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
BR112021015832A2
(pt)
|
2019-02-12 |
2022-01-18 |
Ambrx Inc |
Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos
|
MX2022000742A
(es)
|
2019-07-18 |
2022-02-14 |
Enyo Pharma |
Metodo para disminuir los efectos adversos del interferon.
|
WO2021178612A1
(en)
|
2020-03-05 |
2021-09-10 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
KR20220151202A
(ko)
|
2020-03-11 |
2022-11-14 |
암브룩스, 인코포레이티드 |
인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
|
WO2021228983A1
(en)
|
2020-05-13 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
|
EP3912627B1
(en)
|
2020-05-20 |
2022-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of coronavirus infections
|
CA3185614A1
(en)
|
2020-06-22 |
2021-12-30 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis d virus infection
|
CA3128035A1
(en)
|
2020-08-13 |
2022-02-13 |
Bioasis Technologies, Inc. |
Combination therapies for delivery across the blood brain barrier
|
JP2023538071A
(ja)
|
2020-08-20 |
2023-09-06 |
アンブルックス,インコーポレイテッド |
抗体-tlrアゴニストコンジュゲート、その方法及び使用
|
WO2022043496A2
(en)
|
2020-08-28 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of mait cells as biomarkers and biotargets in covid-19
|
WO2022079205A1
(en)
|
2020-10-15 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of ifn-alpha polypeptides for the treatment of coronavirus infections
|
CA3213805A1
(en)
|
2021-04-03 |
2022-10-06 |
Feng Tian |
Anti-her2 antibody-drug conjugates and uses thereof
|